Aerosolized formulations of HIV protease inhibitors for the treatment of airway reflux
The present invention provides methods of treating airway reflux using an HIV protease inhibitor that is capable of binding to and inhibiting the enzymatic activity of pepsin. Compositions comprising aerosolized formulations of HIV protease inhibitors are also provided.
1 . A method of treating reflux in a subject in need thereof, the method comprising administering a therapeutically effective amount of an HIV protease inhibitor to a subject to treat the reflux, wherein the HIV protease inhibitor is fosamprenavir and wherein the subject has an airway reflux condition selected from laryngopharyngeal reflux (LPR), gastropharyngeal reflux (GPR), and esophagopharyngeal reflux (EPR).
2 . The method of claim 1 , wherein the HIV protease inhibitor is capable of binding to and inhibiting the enzymatic activity of pepsin.
3 . The method of claim 1 , wherein the HIV protease inhibitor is administered orally.
4 . The method of claim 1 , wherein the HIV protease inhibitor is administered as an aerosol.
5 . The method of claim 4 , wherein the HIV protease inhibitor is administered as a nasal spray.
6 . The method of claim 4 , wherein the HIV protease inhibitor is administered via an inhaler or nebulizer.
7 . The method of claim 1 , wherein the HIV protease inhibitor is administered twice daily at a dosage of about 1.4 g or lower.
8 . The method of claim 1 , wherein the subject's condition is refractory to treatment with a proton pump inhibitor (PPI).
9 . The method of claim 1 , wherein the method reduces laryngeal mucosal damage and inflammation.
10 . The method of claim 1 , wherein the subject has gastroesophageal reflux disease (GERD).
11 . The method of claim 10 , wherein the subject's GERD is refractory to treatment with a proton pump inhibitor (PPI).